期刊文献+

抗人CD3嵌合抗体基因的构建、表达及表达产物的初步功能研究 被引量:4

Construction and expression of anti-human CD3 chimeric antibody gene and preliminary study of expressed product
原文传递
导出
摘要 目的: 构建并表达抗人CD3嵌合抗体, 以克服鼠源单克隆抗体(mAb)用于临床的局限性。方法: 采用基因工程技术, 将抗体VL、VH 基因分别克隆入嵌合抗体表达载体VLExpress及VHExpress中。共转染COS- 7细胞后, 用ELISA检测培养上清中嵌合抗体的表达水平; 采用ProteinA亲和层析法纯化抗体, 并进行Westernblot鉴定。用FACS检测嵌合抗体结合抗原的活性; 混合淋巴细胞培养检测抗体的功能。结果: 成功地构建了VH Express VH 及VLExpress VL表达载体并表达纯化。Westernblot的结果显示, 表达的抗人CD3抗体为人鼠嵌合抗体。FACS的结果显示, 该抗体具有良好的结合抗原活性; 混合淋巴细胞培养结果显示, 该抗体具有一定的免疫抑制功能。结论: 成功地构建、表达了抗人CD3嵌合抗体, 为进一步的研究打下了基础。 AIM: To construct and express anti-human CD3 chimeric antibody. METHODS: The genes of variable regions of the light chain (V L) and heavy chain (V H) were cloned respectively into the expression vectors (V L Express, V H Express), and co-transfected into COS-7 cells. Expression level of the chimeric antibody in culture supernatant was detected by ELISA. The antibody was purified through protein A affinity chromatography and identified by Western blot. Binding activity of the chimeric antibody to the antigen was determined by FACS. Biological activity of the chimeric antibody was determined by mixed T-lymphocyte culture test. RESULTS: The expression vectors were constructed and the anti-human CD3 chimeric antibody was expressed and purified successfully. Western blot showed that the purified antibody was human-mouse chimeric antibody. FACS result showed that the chimeric antibody had antigen-binding activity. Mixed T-lymphocyte culture test showed that the chimeric antibody could suppress proliferation of T lymphocytes. CONCLUSION: The anti-human CD3 chimeric antibody has been constructed and expressed successfully, which lays the foundation for its further study.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2005年第1期43-45,49,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家重点基础研究发展规划(973)资助(No. 2003CB515508)
关键词 CD3 嵌合抗体 混合淋巴细胞培养 免疫抑制 CD3 chimeric antibody mixed T-lymphocyte culture immune suppression
  • 相关文献

参考文献7

  • 1萨姆布鲁克 J 拉塞尔 DW(黄培堂 等译).分子克隆实验指南[M].第3版[M].北京: 科学出版社,2002.2-137.
  • 2奥斯伯F(颜子颖 王海林 译).精编分子生物学实验指南[M].北京:科学出版社,2001.366-373.
  • 3向军俭,李洪庆,邓宁,杨红宇,童贻刚,李建民.抗rh-bFGF嵌合抗体真核表达载体的构建与表达[J].细胞与分子免疫学杂志,2004,20(2):163-167. 被引量:5
  • 4Chatenoud L. CD3-specific antibody-induced active tolerance:form bench to bedside[J]. Immunology, 2003, 3: 123-132.
  • 5Renders L, Valerius T. Engineered CD3 antibodies for immunosuppression[J]. Clin Exp. Immunol, 2003, 133: 307-309.
  • 6Choi I, Schmitt WE, Bahre A, et al. Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model[J]. Immunolgy Letter, 2002, 80: 125-128.
  • 7Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-type I diabetes mellitus[J]. N Engl J Med, 346(22): 1692-1698.

二级参考文献12

  • 1Brick A, Kirkin AF, Zeuthen J, et al. Expression of basis fibroblastgrowth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patiens[ J]. Melanoma Res, 1999, 9(4): 375 -381.
  • 2Dietz A, Rudat V, Vanselow B, et al. Predictive value of serum levelsof basis fibroblast groth factor vascular endothelial growth factor andmatrix maet alloproteinase-2 advanced carcinomas of the head and neck[J]. HNO, 1999, 47(8): 695 -701.
  • 3Bodo M, Baroni T, Bellocchio S. Bronchial epithelial cell matrix production in response to silica and basic fibroblast growth factor[ J ]. MolMed, 2001, 7(2): 83 -92.
  • 4Coppola G, Atlas-White M, Katsahambas S, et al. Effect of intraperitoneally, intravenously and intralesionally administered monoclonalanti-beta- FGF antibodies on rat chondrosarcom a tumor vasculerizationand growth[J]. Anticacer Res, 1997, 17(3C): 2033 -2
  • 5Sambrok J, Frisch EF, Maniatis T. Molecular cloning: A LaboratoryManual [ M ], 2ed, Beijing. Science press, 1996:42 - 59,880 - 897.
  • 6Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs [ J]. Ann Allergy Asthma Immunol, 1998, 81 ( 2 ):105 - 115.
  • 7Heinzerling L, Dummer R, Kempf W, et al. Intralesional therapy withanti-CD20 monoclonal antibody rituximab in primary cutaneous B-celllymphoma[J]. Arch Dermatol, 2000, 136(3): 374 -378.
  • 8Vaughan T, Osboum JK, Tempest PR, et al. Human antibodies bydesign [J]. Nat Biotech, 1998, 16:535 -539.
  • 9向军俭,刘小青,黄立,刘嵘,梁秋健.抗bFGF单克隆抗体的鉴定及其意义[J].细胞与分子免疫学杂志,1998,14(4):275-277. 被引量:1
  • 10冉宇靓,孔健,杨治华,孙立新,刘军,陈凤,遇珑.抗CEA抗体可变区基因的克隆及其嵌合抗体的表达[J].实用肿瘤杂志,2001,16(2):82-86. 被引量:3

共引文献5

同被引文献45

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部